News

ReAlta Life Sciences Further Bolsters Experienced Executive Team with the Appointment of Peter Ho, Ph.D., as Head of Business Development and Corporate Strategy

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, announced that Peter Ho, Ph.D., has joined the Company as Head of Business Development and Corporate Strategy.

“I am thrilled to have Peter join our executive team at this pivotal time as we advance our three Phase 2 programs in rare and acute inflammatory diseases,” said David Marek, Chief Executive Officer of ReAlta. “Peter’s expertise in business development and corporate strategy, which spans biopharmaceutical companies of all sizes and stages, will be a tremendous asset for ReAlta as we look to maximize opportunities for our platform.”

“ReAlta has key inflection points in the near future across the Company’s three lead clinical programs in hypoxic ischemic encephalopathy (HIE), acute graft-versus-host disease (aGvHD), and acute exacerbations of chronic obstructive pulmonary disease (AE-COPD), as well as a promising and unique platform to generate additional assets with the potential to address huge unmet needs in both acute and chronic inflammatory diseases,” said Dr. Ho. “I look forward to working with Dave and the rest of the ReAlta team to identify opportunities to create value for the company and, most importantly, for patients facing life-threatening diseases.”

Dr. Ho has more than 20 years of biopharmaceutical industry experience. Prior to joining ReAlta, he was Head of Cell Therapy Business Development at Ginkgo Bioworks. He has held senior business development roles at a variety of biotechnology companies, including Nektar Therapeutics, BeiGene, Iovance, and Allergan. Dr. Ho has also led negotiations to execute drug discovery collaborations and clinical development partnerships, as well as license agreements. Earlier in his career, he worked in early-stage drug company investments at D.E. Shaw, in finance as an equity research analyst covering major pharmaceutical companies, as well as in advertising and communications at Grey Healthcare Group. Dr. Ho has an MBA from the UCLA Anderson School of Management, a Ph.D. in biology from the University of California, San Diego, and undergraduate degrees in chemistry and biology from the University of California, Irvine.

Learn more here.

Recent News

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive

07/01/2025

Gary Lowenthal Joins Focused Ultrasound Foundation’s Council

The Focused Ultrasound Foundation is pleased to welcome Gary Lowenthal to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide advice and assist with raising funds and building awareness. Mr. Lowenthal is a retired educator, entrepreneur, and executive with a career spanning education, international service,

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital